Can a new asthma inhaler match the standard of care?

NCT ID NCT07768891

NEW Recruiting now Disease control Sponsor: Lunan Better Pharmaceutical Co., LTD. Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This study tests whether a new combination inhaler, containing beclometasone dipropionate and formoterol, works as well as an existing treatment (FOSTER®) for people with asthma. About 416 adults with asthma will use one of the two inhalers twice daily for four weeks. Researchers will measure changes in lung function and monitor for side effects to see if the new inhaler is a viable alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Beclometasone dipropionate and formoterol inhalation aerosol
What this could lead to: If successful, this could provide another effective and safe treatment option for people with asthma.
What could go wrong: This is a phase 3 trial, but it's still possible the new inhaler won't be as effective or safe as the standard one. Results may not apply to all asthma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA (DIAGNOSIS)

Contacts and locations

Locations

Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.